Other Tumor Types: 18F-FDG PET/CT for Response Assessment of Various Tumors Following Immunotherapy

  • Egesta Lopci
  • Angelo Castello


Immunotherapy with checkpoint blockade represents the standard therapy for multiple malignancies, including melanoma, NSCLC, cHL, renal cell carcinoma (RCC), bladder cancer, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), Merkel cell carcinoma, colorectal cancer (CRC) with microsatellite instability high (MSI-H) or DNA mismatch repair deficient (dMMR), and so forth. Along with the examples presented in the previous chapters, herein we report some additional case reports illustrating response to immunotherapy in other tumor types.


Immunotherapy Solid tumors Response assessment Colorectal cancer Squamous cell carcinoma Merkel cell carcinoma 


  1. 1.
    Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–74. eCollection 2019.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.CrossRefGoogle Scholar
  3. 3.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefGoogle Scholar
  4. 4.
    Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.CrossRefGoogle Scholar
  5. 5.
    Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–91.CrossRefGoogle Scholar
  6. 6.
    Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Egesta Lopci
    • 1
  • Angelo Castello
    • 1
  1. 1.Nuclear MedicineHumanitas Clinical and Research Hospital - IRCCSRozzanoItaly

Personalised recommendations